Ecopipam (UNII-0X748O646K) is a potent, selective, and orally active antagonist of dopamine D1/D5 receptors, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam demonstrates more than 40-fold selectivity over D2, D4, 5-HT, and alpha2a receptors (Ki=0.98, 5.52, 0.08, and 0.73 µM, respectively). It is used in research on schizophrenia and obesity.
